NCT06123715 Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty
| NCT ID | NCT06123715 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University Health Network, Toronto |
| Condition | Chronic Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-04-16 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 400 participants in total. It began in 2024-04-16 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Phase II Multicentre, pilot, parallel-group, blinded, 1:1 randomized controlled trial to determine the feasibility of conducting a larger definitive trail of using vitamin C to reduce persistent pain in patients undergoing total knee arthroplasty surgery.
Eligibility Criteria
Inclusion Criteria: * Patients \>18 years old * Undergoing a unilateral or bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee Exclusion Criteria: * TKA for infection (septic joint), fracture, ankylosing spondylitis, lupus, or psoriatic arthritis * History of kidney stones, acute or chronic renal failure, hemochromatosis, or glucose-6-phosphate deficiency * Unlikely to comply with follow-up (e.g., no fixed address, plans to move out of town) * Language difficulties that would impede valid completion of questionnaires * Planned staged bilateral TKA * Treating surgeon deems patient inappropriate for inclusion in trial * Any allergy or sensitivity to milk * Pregnant or planning to become pregnant during the study
Contact & Investigator
James Khan, MD
PRINCIPAL INVESTIGATOR
University Health Network; Department of Anesthesia and Pain Medicine
Frequently Asked Questions
Who can join the NCT06123715 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06123715 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06123715 currently recruiting?
Yes, NCT06123715 is actively recruiting participants. Contact the research team at James.Khan@medportal.ca for enrollment information.
Where is the NCT06123715 trial being conducted?
This trial is being conducted at Toronto, Canada, Toronto, Canada, Toronto, Canada.
Who is sponsoring the NCT06123715 clinical trial?
NCT06123715 is sponsored by University Health Network, Toronto. The principal investigator is James Khan, MD at University Health Network; Department of Anesthesia and Pain Medicine. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.